NAMs MENOPAUSE CERTIFICATION EXAM 2025-2026
ACTUAL EXAM 250 QUESTIONS AND CORRECT
ANSWERS) |ALREADY GRADED A+
Overview:
This updated test bank reflects the latest 2025–2026 exam content, emphasizing
evidence-based guidelines for the care of women during perimenopause,
menopause, and postmenopause. Each question is paired with the correct answer,
making it an excellent preparation tool to help learners achieve top performance on
the certification exam.
Key Features:
250 verified exam questions with correct answers.
Aligned with 2025–2026 NAMS exam content and guidelines.
Covers hormone therapy, osteoporosis, cardiovascular health, sexual
health, cancer screening, lifestyle interventions, and psychosocial
aspects.
Verified accuracy with A+ graded content.
Ideal for self-testing, practice, and exam preparation.
Purpose:
To provide healthcare professionals with a comprehensive and reliable exam
preparation tool for the NAMS Menopause Certification Exam, ensuring a deeper
understanding of midlife and aging women’s health management.
Recommended For:
Physicians, nurse practitioners, physician assistants, pharmacists, and other
clinicians seeking NAMS Menopause Certification.
Professionals aiming to expand expertise in menopause and healthy aging
care.
Educators and mentors preparing candidates for women’s health
certification exams.
,Climacteric phase - ANSWER-The period of endrocrinologic, somatic, and transitory
psychologic changes that occur around the time of menopause.
Early menopause - ANSWER-LMP before age 45
Late menopause - ANSWER-LMP after age 54
Primary ovarian insufficiency - ANSWER-Menopause that occurs before age 40
Early menopause transition (stage -2) - ANSWER-Persistent difference of 7 days or
more in the length of consecutive cycles.
Late menopause transition (stage -1) - ANSWER-60 or more consecutive days of
amenorrhea
Luteal out of phase event (LOOP) - ANSWER-Explains why some perimenopausal
women have elevated estrogen level sometimes...In the early menopause transition,
elevated FSH levels are adequate to recruit a second follicle which results in a follicular
phase-like rise in estradiol secretion superimposed on the mid-to-late luteal phase of the
ongoing ovulatory cycle.
Obese women and estradiol levels during menopause - ANSWER-Obese women are
more likely to have anovulatory cycles with high estradiol levels. They are also more
likely to have lower premenopause yet higher postmenopause estradiol levels
compared with women of normal weight. (why they are at higher risk of endometrial
cancer)
Chinese and Japanese women - ANSWER-These ethnic groups have lower estradiol
levels then white, black and hispanic women.
stage +2 - ANSWER-late menopause stage: 5-8 years after FMP. Somatic aging
predominates. Increased genitourinary symptoms.
Stages +1a, +1b, +1c - ANSWER-early post menopause: 2 years after FMP. FSH rises,
estradiol decreases. VMS predominate.
Elevated FSH, LH - ANSWER-Endocrine labs after menopause
AMH, inhibin B - ANSWER-These hormones work during reproductive years to not
deplete follicle pool too quickly.
, Phases during menopause transition and PMS symptoms - ANSWER-Menstrual cycle
variable, persistent >7 day difference between difference in length of consecutive
cycles.
How to respond if a patient requests FSH lab? - ANSWER-many pitfalls, variable
depending on the day of the cycle you draw the lab, normal or low FSH is not helpful.
The potentially superior marker of menopause, a lab. - ANSWER-AMH
DHEA (dehydroepiandrosterone) - ANSWER-Adrenal androgens: precursor hromones
produced by the adrenal gland that are enzymatically converted to active androgens or
estrogens in peripheral tissues.
Location of estrogen receptors - ANSWER-Vagina, vulva, urethra, trigone of the bladder
Effects of estrogen on tissue - ANSWER-maintain blood flow, the collagen, and HA
within the epithelial surfaces. Supports microbiome which supports acidity of vagina and
protects tissue from pathogens.
Vaginal changes with menopause - ANSWER-Thinning, loss of elasticity, loss or
absence or rugae.
Vagina and urethra in menopause - ANSWER-vagina narrows, urethra moves closer to
the introitus.
Stress urinary incontinence - ANSWER-Vaginal estrogen and urinary incontinence: what
type does it help with?
Treatment for FPHL - ANSWER-Minoxidil, spironolactone, finasteride, estrogen therapy
Late reporoductive years -3b and -3a. What happens with menstrual cycles, FSH, AMH,
AFC, inhibin? - ANSWER--3b: menstrual cycles normal, FSH normal, AMH low, AFC
low, inhibin low.
-3a: subtle menstrual changes, variable FSH, AMH low, AFC low, inhibin low.
When it is appropriate to check an FSH during the cycle if you check it? and why? -
ANSWER-Cycle day #3. Elevated estradiol can suppress FSH giving a falsely normal
FSH level.
AMH
produced by... used
to test...
ACTUAL EXAM 250 QUESTIONS AND CORRECT
ANSWERS) |ALREADY GRADED A+
Overview:
This updated test bank reflects the latest 2025–2026 exam content, emphasizing
evidence-based guidelines for the care of women during perimenopause,
menopause, and postmenopause. Each question is paired with the correct answer,
making it an excellent preparation tool to help learners achieve top performance on
the certification exam.
Key Features:
250 verified exam questions with correct answers.
Aligned with 2025–2026 NAMS exam content and guidelines.
Covers hormone therapy, osteoporosis, cardiovascular health, sexual
health, cancer screening, lifestyle interventions, and psychosocial
aspects.
Verified accuracy with A+ graded content.
Ideal for self-testing, practice, and exam preparation.
Purpose:
To provide healthcare professionals with a comprehensive and reliable exam
preparation tool for the NAMS Menopause Certification Exam, ensuring a deeper
understanding of midlife and aging women’s health management.
Recommended For:
Physicians, nurse practitioners, physician assistants, pharmacists, and other
clinicians seeking NAMS Menopause Certification.
Professionals aiming to expand expertise in menopause and healthy aging
care.
Educators and mentors preparing candidates for women’s health
certification exams.
,Climacteric phase - ANSWER-The period of endrocrinologic, somatic, and transitory
psychologic changes that occur around the time of menopause.
Early menopause - ANSWER-LMP before age 45
Late menopause - ANSWER-LMP after age 54
Primary ovarian insufficiency - ANSWER-Menopause that occurs before age 40
Early menopause transition (stage -2) - ANSWER-Persistent difference of 7 days or
more in the length of consecutive cycles.
Late menopause transition (stage -1) - ANSWER-60 or more consecutive days of
amenorrhea
Luteal out of phase event (LOOP) - ANSWER-Explains why some perimenopausal
women have elevated estrogen level sometimes...In the early menopause transition,
elevated FSH levels are adequate to recruit a second follicle which results in a follicular
phase-like rise in estradiol secretion superimposed on the mid-to-late luteal phase of the
ongoing ovulatory cycle.
Obese women and estradiol levels during menopause - ANSWER-Obese women are
more likely to have anovulatory cycles with high estradiol levels. They are also more
likely to have lower premenopause yet higher postmenopause estradiol levels
compared with women of normal weight. (why they are at higher risk of endometrial
cancer)
Chinese and Japanese women - ANSWER-These ethnic groups have lower estradiol
levels then white, black and hispanic women.
stage +2 - ANSWER-late menopause stage: 5-8 years after FMP. Somatic aging
predominates. Increased genitourinary symptoms.
Stages +1a, +1b, +1c - ANSWER-early post menopause: 2 years after FMP. FSH rises,
estradiol decreases. VMS predominate.
Elevated FSH, LH - ANSWER-Endocrine labs after menopause
AMH, inhibin B - ANSWER-These hormones work during reproductive years to not
deplete follicle pool too quickly.
, Phases during menopause transition and PMS symptoms - ANSWER-Menstrual cycle
variable, persistent >7 day difference between difference in length of consecutive
cycles.
How to respond if a patient requests FSH lab? - ANSWER-many pitfalls, variable
depending on the day of the cycle you draw the lab, normal or low FSH is not helpful.
The potentially superior marker of menopause, a lab. - ANSWER-AMH
DHEA (dehydroepiandrosterone) - ANSWER-Adrenal androgens: precursor hromones
produced by the adrenal gland that are enzymatically converted to active androgens or
estrogens in peripheral tissues.
Location of estrogen receptors - ANSWER-Vagina, vulva, urethra, trigone of the bladder
Effects of estrogen on tissue - ANSWER-maintain blood flow, the collagen, and HA
within the epithelial surfaces. Supports microbiome which supports acidity of vagina and
protects tissue from pathogens.
Vaginal changes with menopause - ANSWER-Thinning, loss of elasticity, loss or
absence or rugae.
Vagina and urethra in menopause - ANSWER-vagina narrows, urethra moves closer to
the introitus.
Stress urinary incontinence - ANSWER-Vaginal estrogen and urinary incontinence: what
type does it help with?
Treatment for FPHL - ANSWER-Minoxidil, spironolactone, finasteride, estrogen therapy
Late reporoductive years -3b and -3a. What happens with menstrual cycles, FSH, AMH,
AFC, inhibin? - ANSWER--3b: menstrual cycles normal, FSH normal, AMH low, AFC
low, inhibin low.
-3a: subtle menstrual changes, variable FSH, AMH low, AFC low, inhibin low.
When it is appropriate to check an FSH during the cycle if you check it? and why? -
ANSWER-Cycle day #3. Elevated estradiol can suppress FSH giving a falsely normal
FSH level.
AMH
produced by... used
to test...
